Biopharmaceutical front-end equipment is accelerating iterative upgrades, and domestic substitution will accelerate in the future

Recently, the domestic pharmaceutical equipment giant Chutian Technology released nearly 20 products with technological innovation and iterative upgrade results.
This news has aroused great attention in the industry
.
Pharmaceutical equipment (picture source: Pharmaceutical Network) It is reported that among the nearly 20 products, there are wave bioreactors, fully automatic microcarrier suspension culture bioreactors, basket bioreactors, disposable liquid mixing and stirring systems, etc.
The front-end process equipment of biopharmaceuticals has all debuted for the first time, and the focus on the development of biomedical equipment, especially biopharmaceutical front-end equipment, consumables, and auxiliary materials, is in line with the established strategy of Chutian Technology
.
In fact, in order to lay out the biopharmaceutical industry chain, Chutian Holdings subsidiary Chutian Siyoute Biology has established a subsidiary in Shanghai this year, and is building a plant of about 6,000 square meters in Shanghai Lingang.
After completion, it can achieve a production capacity of 200 million yuan.
It is used for the development and production of disposable bioreactors, liquid distribution bags, liquid storage bags and their membrane materials
.
It is understood that the blockbuster new product unveiled this time-the wave-type bioreactor is developed by Siyoute Biotechnology.
The reactor equipment can be used for cell therapy, antibody drug seed amplification and vaccine production, ensuring no Bacteria environment reduces the risk of pollution
.
Guosen Securities once pointed out in a report that the proportion of China's high-end pharmaceutical equipment market has increased from 24% in 2015 to 28% in 2019
.
With the rapid development of the biopharmaceutical industry, it is expected that the market share of high-end pharmaceutical equipment will gradually increase, and it is expected to further increase to 32% in 2024
.
In this context, domestic biopharmaceutical equipment companies that are the first to deploy in the high-end field are expected to usher in opportunities
.
However, biopharmaceutical equipment can be divided into front-end equipment and middle and back-end equipment.
At present, domestic pharmaceutical equipment companies mainly develop rapidly in the middle and back-end equipment field and have the ability to replace imports.
However, they mainly rely on front-end equipment.
Import, which has a certain relationship with the higher technical threshold of front-end equipment
.
According to the survey activity information released by Chutian Technology on December 14, in view of the advantages and disadvantages of the company’s products compared with domestic and international counterparts, the company said that the main technical feature of biological front-end products is the manufacturability of manufacturing technology.
The feature of the middle and back stage products is equipment.
From a certain point of view, the front end is more difficult to process than the middle and back stages.

.
At present, the neck clamping technology is mainly in the front end of biology, and the technology of the middle and rear products has been relatively mature, and there is no place for neck clamping
.
It also pointed out that the competitiveness of mid-to-late products is a process of long-term accumulation, and companies must have a deep craftsmanship to do a good job, through the improvement of manufacturing technology and the improvement of quality assurance system over the past years
.
It can be seen that domestic pharmaceutical equipment companies still need to continue to work hard at the front end to break through the technical problems of stuck necks.
This process is naturally arduous and long, requiring high-end talents, R&D investment, and policies
.
In the middle and late stages, companies also need to pay attention to the cultivation of craftsmanship, continue to improve manufacturing levels, and improve product quality in order to share more shares in the high-end pharmaceutical equipment market and further accelerate the pace of domestic substitution
.
At present, many domestic manufacturers have already sensed business opportunities and have become more determined to take the high-end route.
For example, a reactor manufacturer stated at the 87th API China this year that the company is moving in the mid-to-high-end direction, and it will continue in the future.
Expand the mid-to-high-end market to meet customer needs; Canaan Technology stated on the investor interaction platform on December 9 that the company’s current business segment includes innovative medical water equipment for biological preparations and pharmaceutical liquid dispensing system engineering businesses.
In the future, the company will rely on The pharmaceutical water equipment and pharmaceutical liquid dispensing system business extends the industrial chain to the front-end and back-end equipment of biological medicine
.
With the continuous efforts of more domestic pharmaceutical equipment companies, it is believed that the front-end equipment of biopharmaceuticals will also accelerate the iterative upgrade, and the domestic substitution will be further accelerated in the future, helping China's biopharmaceutical industry to develop with higher quality
.